The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
Abstract
Prognosis of multiple sclerosis is highly variable. Clinical variables have been identified that are assessable early in the disease and are predictors of the time from the disease onset to the onset of irreversible disability. Our objective was to determine if these clinical variables still have an effect after the first stages of disability have been reached. We determined the dates of disease onset and assignment of scores of irreversible disability in 1844 patients with multiple sclerosis. We used three scores on the Kurtzke Disability Status Scale as benchmarks of disability accumulation: 4 (limited walking but without aid); 6 (walking with unilateral aid); and 7 (wheelchair bound). We used Kaplan-Meier analyses and Cox regression models to determine the influence of the clinical variables on the time to disability onset. Median times from onset of multiple sclerosis to assignment of a score of 4, 6 and 7 were significantly influenced by gender, age, symptoms and course (relapsing-remitting or progressive) at onset of the disease, degree of recovery from the first relapse, time to a second neurological episode, and the number of relapses in the first 5 years of the disease. Similarly, times from onset of multiple sclerosis to a score of 6 and 7 were influenced by time to a score of 4. In contrast, none of the variables substantially affected the time from a score of 4 to a score of 6 or 7, or from a score of 6 to a score of 7. Early assessable clinical variables significantly influence the time from the onset of multiple sclerosis to the assignment of a disability score of 4, but not the subsequent progression of irreversible disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Self-citationThe natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
(2006) · Elsevier eBooks · doi:10.1016/b978-0-443-07271-0.x5001-0 · Cited by 769
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Cited by
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Self-citationThe Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905
Self-citationFisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
The epidemiology of multiple sclerosis in Europe
Pugliatti, M., Rosati, G., Carton, H., Riise, T., Drulovic, J., Vécsei, L., & Milanov, I. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01342.x · Cited by 654
Multiple sclerosis: clinical aspects
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000622 · Cited by 620
Natural History of Multiple Sclerosis with Childhood Onset
Renoux, C., Vukusic, S., Mikaeloff, Y., Edan, G., Clanet, M., Dubois, B., Debouverie, M., Brochet, B., Lebrun-Frenay, C., Pelletier, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067597 · Cited by 598
Self-citationEvidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Genetics of multiple sclerosis
Dyment, D. A., Ebers, G. C., & Dessa Sadovnick, A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00663-x · Cited by 563
Defining high, medium, and low impact prognostic factors for developing multiple sclerosis
Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain · doi:10.1093/brain/awv105 · Cited by 530
Age at disability milestones in multiple sclerosis
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awh714 · Cited by 525
Self-citationMitchell, A. J., Benito-León, J., González, J.-M. M., & Rivera-Navarro, J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70166-6 · Cited by 519
The epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Epidemiology of multiple sclerosis
Leray, E., Moreau, T., Fromont, A., & Edan, G. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.006 · Cited by 478
Silent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
The natural history of multiple sclerosis with childhood onset
Renoux, C., Vukusic, S., & Confavreux, C. (2008) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2008.04.009 · Cited by 450
Self-citationKremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3537 · Cited by 418
Defining secondary progressive multiple sclerosis
Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2016) · Brain · doi:10.1093/brain/aww173 · Cited by 415
The benefits of exercise training in multiple sclerosis
Motl, R. W., & Pilutti, L. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.136 · Cited by 394
Hanamsagar, R., & Bilbo, S. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.09.039 · Cited by 374
Disability progression in multiple sclerosis is slower than previously reported
Tremlett, H., Paty, D., & Devonshire, V. (2006) · Neurology · doi:10.1212/01.wnl.0000194259.90286.fe · Cited by 343
Stroke and the Risk of Alzheimer Disease
Honig, L. S., Tang, M.-X., Albert, S., Costa, R., Luchsinger, J., Manly, J., Stern, Y., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1707 · Cited by 343
Radiologically isolated syndrome: 5-year risk for an initial clinical event
Okuda, D. T., Siva, A., Kantarci, O., Inglese, M., Katz, I., Tutuncu, M., Keegan, B. M., Donlon, S., Hua, L. H., Vidal-Jordana, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090509 · Cited by 339
“Similar outcomes are also observed in men [19].”
ResultSwanton, J. K., Rovira, A., Tintore, M., Altmann, D. R., Barkhof, F., Filippi, M., Huerga, E., Miszkiel, K. A., Plant, G. T., Polman, C., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70176-x · Cited by 330
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
Kieseier, B. C. (2011) · CNS Drugs · doi:10.2165/11591110-000000000-00000 · Cited by 308
Secondary progressive multiple sclerosis: current knowledge and future challenges
Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., & Filippi, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70410-0 · Cited by 303
Self-citationClinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis
Cree, B. A. C., Khan, O., Bourdette, D., Goodin, D. S., Cohen, J. A., Marrie, R. A., Glidden, D., Weinstock-Guttman, B., Reich, D., Patterson, N., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000145762.60562.5d · Cited by 301
The molecular basis of neurodegeneration in multiple sclerosis
Lassmann, H., & van Horssen, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.004 · Cited by 294
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Age and disability accumulation in multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Ebers, G. C., & Muraro, P. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a17d · Cited by 279
Inflammation, demyelination, and degeneration — Recent insights from MS pathology
Stadelmann, C., Wegner, C., & Brück, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.007 · Cited by 276
The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
Minden, S. L., Frankel, D., Hadden, L., Perloff, J., Srinath, K. P., & Hoaglin, D. C. (2006) · Multiple Sclerosis Journal · doi:10.1191/135248506ms1262oa · Cited by 272
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Sex-related factors in multiple sclerosis susceptibility and progression
Voskuhl, R. R., & Gold, S. M. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.43 · Cited by 262
New perspectives in the natural history of multiple sclerosis
Tremlett, H., Zhao, Y., Rieckmann, P., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e3973f · Cited by 261
Villar, L. M., Sádaba, M. C., Roldán, E., Masjuan, J., González-Porqué, P., Villarrubia, N., Espiño, M., García-Trujillo, J. A., Bootello, A., & Álvarez-Cermeño, J. C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522833 · Cited by 259
Hanna, M., & Strober, L. B. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102261 · Cited by 202
Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Grand’Maison, F., Hupperts, R., Grammond, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122686 · Cited by 190
“Male sex has been associated with a faster time to reaching EDSS milestones 4, 6 and 7 in the Lyon population [8], but not in the London Ontario group, where sex failed to impact on time to earlier EDSS milestones but EDSS 10 (death) was reached faster by male patients [37].”
BackgroundMethodResultInfluentialEpidemiology and natural history of multiple sclerosis: new insights
Kantarci, O., & Wingerchuk, D. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000227033.47458.82 · Cited by 156
Clinical characteristics of patients with late-onset multiple sclerosis
Kis, B., Rumberg, B., & Berlit, P. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0778-x · Cited by 137
Taylor, L. C., Gilmore, W., Ting, J. P. ‐., & Matsushima, G. K. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22215 · Cited by 123
“However, gender may also have subtle effects on disease severity, as illustrated by a natural history study in which females showed an association with slower progression of disease (Confavreux et al., 2003).”
BackgroundThe effect of sex on multiple sclerosis risk and disease progression
Voskuhl, R. R. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519892491 · Cited by 113
Tintore, M., Cobo-Calvo, A., Carbonell, P., Arrambide, G., Otero-Romero, S., Río, J., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012726 · Cited by 90
Clinically isolated syndromes and the relationship to multiple sclerosis
Brownlee, W. J., & Miller, D. H. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.02.026 · Cited by 84
Gamache, J., Yun, Y., & Chiba-Falek, O. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045211 · Cited by 84
Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis
Putzki, N., Fischer, J., Gottwald, K., Reifschneider, G., Ries, S., Siever, A., Hoffmann, F., Käfferlein, W., Kausch, U., Liedtke, M., et al. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02572.x · Cited by 80
“5) and may become wheelchair-bound after about 30 years on average [1].”
BackgroundThe Novo Group, Fernández, O., Fernández, V., Arbizu, T., Izquierdo, G., Bosca, I., Arroyo, R., García Merino, J. A., & de Ramón, E. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5560-1 · Cited by 69
Early predictors of conversion to secondary progressive multiple sclerosis
Barzegar, M., Najdaghi, S., Afshari-Safavi, A., Nehzat, N., Mirmosayyeb, O., & Shaygannejad, V. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103115 · Cited by 52
Jackson, S. J., Lee, J., Nikodemova, M., Fabry, Z., & Duncan, I. D. (2009) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e3181a41d23 · Cited by 38
Alroughani, R., Al Hashel, J., Lamdhade, S., & Ahmed, S. F. (2012) · ISRN Neurology · doi:10.5402/2012/792192 · Cited by 28
The initial course of daily functioning in multiple sclerosis: a three-year follow-up study
de Groot, V, Beckerman, H., Lankhorst, G. J., Polman, C. H., & Bouter, L. M. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1238oa · Cited by 23
Metadata
- Authors
- Confavreux, C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-01
- Volume
- 126
- Issue
- 4
- Pages
- 770-782
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2148186809
- Cited by
- 996
- References
- 33
- FWCI
- 20.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.